drugset / Trial / NCT07107256
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
Phase 3
Recruiting
246 enrolled
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
TQC2731 injection is a humanized monoclonal antibody that targets Thymic Stromal Lymphopoietin (TSLP), blocks the TSLP pathway, and inhibits the production of downstream cytokines, thereby exerting anti-inflammatory effects. The purpose of this study is to evaluate the efficacy and safety of TQC2731 injection in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Timeline
- Start
- 2025-09-25
- Primary completion
- 2027-03
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TQC2731 | Monoclonal antibody | — | — |